Tafamidis in transthyretin amyloidosis: a guide to its use in delaying peripheral neurological impairment in patients with stage 1 polyneuropathy

[1]  D. Adams,et al.  Familial amyloid polyneuropathy , 2017, Current opinion in neurology.

[2]  L. Amass,et al.  Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy , 2016, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[3]  M. Russo,et al.  Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area , 2016, Journal of Neurology.

[4]  H. Morita,et al.  Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study , 2016, Journal of the Neurological Sciences.

[5]  V. Algalarrondo,et al.  TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies , 2016, Expert opinion on pharmacotherapy.

[6]  R. Labaudinière,et al.  Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis , 2016, Neurology and Therapy.

[7]  O. Suhr,et al.  Survival After Transplantation in Patients With Mutations Other Than Val30Met: Extracts From the FAP World Transplant Registry , 2016, Transplantation.

[8]  P. Hawkins,et al.  Evolving landscape in the management of transthyretin amyloidosis , 2015, Annals of medicine.

[9]  T. Coelho,et al.  Familial Amyloid Polyneuropathy treatment with Tafamidis – evaluation of one- and two-year treatment in Porto, Portugal , 2015, Orphanet Journal of Rare Diseases.

[10]  M. Stewart,et al.  Positive real-world effectiveness of tafamidis for delaying disease progression in transthyretin familial amyloid polyneuropathy , 2015, Orphanet Journal of Rare Diseases.

[11]  N. Heaton,et al.  Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative? , 2015, Transplantation.

[12]  R. Falk,et al.  Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. , 2015, Circulation. Heart failure.

[13]  O. Karayal,et al.  Post Hoc Analysis of Nutritional Status in Patients with Transthyretin Familial Amyloid Polyneuropathy: Impact of Tafamidis , 2014, Neurology and Therapy.

[14]  L. Scott.  Tafamidis: A Review of Its Use in Familial Amyloid Polyneuropathy , 2014, Drugs.

[15]  Y. Sekijima.  Recent progress in the understanding and treatment of transthyretin amyloidosis , 2014, Journal of clinical pharmacy and therapeutics.

[16]  V. Algalarrondo,et al.  FAP Neuropathy and Emerging Treatments , 2014, Current Neurology and Neuroscience Reports.

[17]  T. Tripp,et al.  Effects of Tafamidis on Transthyretin Stabilization and Clinical Outcomes in Patients with Non-Val30Met Transthyretin Amyloidosis , 2013, Journal of Cardiovascular Translational Research.

[18]  Teresa Coelho,et al.  Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy , 2013, Journal of Neurology.

[19]  I. Merkies.  Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial , 2013, Neurology.

[20]  Yukio Ando,et al.  Guideline of transthyretin-related hereditary amyloidosis for clinicians , 2013, Orphanet Journal of Rare Diseases.

[21]  R. Labaudinière,et al.  Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade , 2012, Proceedings of the National Academy of Sciences.

[22]  M. Saadeh,et al.  Liver , 2016, Laboratory Investigation.